Cetera Investment Advisers’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.11M | Sell |
22,444
-1,059
| -5% | -$195K | ﹤0.01% | 1658 |
|
|
2025
Q4 | $4.14M | Buy |
23,503
+2,615
| +13% | +$427K | ﹤0.01% | 1600 |
|
|
2025
Q3 | $2.93M | Buy |
20,888
+8,000
| +62% | +$1.08M | ﹤0.01% | 1844 |
|
|
2025
Q2 | $1.62M | Buy |
12,888
+280
| +2% | +$34.9K | ﹤0.01% | 2008 |
|
|
2025
Q1 | $1.73M | Sell |
12,608
-661
| -5% | -$94.5K | ﹤0.01% | 1850 |
|
|
2024
Q4 | $2.03M | Buy |
13,269
+400
| +3% | +$67.5K | ﹤0.01% | 1647 |
|
|
2024
Q3 | $2.49M | Sell |
12,869
-1,105
| -8% | -$231K | 0.01% | 1467 |
|
|
2024
Q2 | $3.24M | Sell |
13,974
-886
| -6% | -$193K | 0.01% | 1240 |
|
|
2024
Q1 | $3.2M | Buy |
14,860
+10,425
| +235% | +$2.44M | 0.01% | 1242 |
|
|
2023
Q4 | $1.15M | Buy |
4,435
+4
| +0.1% | +$982 | 0.01% | 1035 |
|
|
2023
Q3 | $1.14M | Buy |
4,431
+296
| +7% | +$79.2K | 0.01% | 991 |
|
|
2023
Q2 | $1.18M | Sell |
4,135
-61
| -1% | -$18.2K | 0.01% | 990 |
|
|
2023
Q1 | $1.17M | Buy |
4,196
+123
| +3% | +$34K | 0.01% | 960 |
|
|
2022
Q4 | $1.13M | Buy |
4,073
+2,148
| +112% | +$607K | 0.01% | 944 |
|
|
2022
Q3 | $514K | Sell |
1,925
-1,487
| -44% | -$316K | 0.01% | 973 |
|
|
2022
Q2 | $696K | Sell |
3,412
-11
| -0.3% | -$2.25K | 0.01% | 933 |
|
|
2022
Q1 | $721K | Sell |
3,423
-391
| -10% | -$85K | 0.01% | 949 |
|
|
2021
Q4 | $915K | Sell |
3,814
-123
| -3% | -$31.6K | 0.01% | 844 |
|
|
2021
Q3 | $1.11M | Sell |
3,937
-434
| -10% | -$142K | 0.02% | 734 |
|
|
2021
Q2 | $1.51M | Buy |
4,371
+227
| +5% | +$68.8K | 0.02% | 612 |
|
|
2021
Q1 | $1.16M | Sell |
4,144
-615
| -13% | -$166K | 0.02% | 609 |
|
|
2020
Q4 | $1.17M | Buy |
4,759
+4,026
| +549% | +$1.04M | 0.02% | 610 |
|
|
2020
Q3 | $208K | Buy |
+733
| New | +$204K | 0.02% | 590 |
|
|
2020
Q2 | – | Sell |
-797
| Closed | -$252K | – | 615 |
|
|
2020
Q1 | $252K | Buy |
+797
| New | +$242K | 0.03% | 438 |
|
|
2019
Q1 | – | Sell |
-707
| Closed | -$212K | – | 488 |
|
|
2018
Q4 | $212K | Sell |
707
-2
| -0.3% | -$638 | 0.03% | 411 |
|
|
2018
Q3 | $250K | Buy |
+709
| New | +$244K | 0.04% | 407 |
|
|
2016
Q3 | – | Sell |
-870
| Closed | -$208K | – | 284 |
|
|
2016
Q2 | $208K | Sell |
870
-13
| -1% | -$3.43K | 0.08% | 272 |
|
|
2016
Q1 | $230K | Sell |
883
-2
| -0.2% | -$528 | 0.1% | 235 |
|
|
2015
Q4 | $273K | Buy |
+885
| New | +$254K | 0.13% | 197 |
|
Other funds holding BIIB
VCM
VPM
Cetera Investment Advisers's BIIB Position: Q1 2026 in Review
Cetera Investment Advisers reduced its Biogen (BIIB) stake by 4.5% in Q1 2026, selling an estimated $195K and leaving 22,444 shares worth $4.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1658.
Cetera Investment Advisers first reported a position in BIIB in Q4 2015 and has held it in 29 quarters since. The position peaked at $4.14M in Q4 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Cetera Investment Advisers held 22,444 shares of Biogen worth $4.11M as of Q1 2026.
- Cetera Investment Advisers sold 1,059 Biogen shares in Q1 2026, an estimated $195K.
- Biogen made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #1658 holding.
- Cetera Investment Advisers first reported a position in Biogen in Q4 2015 and has held it in 29 quarters since.
- Cetera Investment Advisers's Biogen position peaked at $4.14M in Q4 2025.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.